Hypertension is associated with serious, life-threatening events, including stroke, heart failure and renal disease. Consequently, both the American College of Cardiology and the American Heart Association have developed guidelines recommending strict blood pressure (BP) control 1 . The findings of the SPRINT and ACCORD trials indicate that intensive lowering of systolic BP below 120 mmHg versus standard lowering below 140 mmHg reduces the risk of death and of adverse cardiovascular events in hypertensive individuals 2, 3 . However, the SPRINT data also suggest that intensive BP lowering might increase the risk (by 3.5-fold) of incident chronic kidney disease (CKD), defined as a ≥30% decrease in estimated glomerular filtration rate (eGFR) to ≤60 ml/min/1.73 m 2 .
To assess whether intensive control of systolic BP does affect renal function, Beddhu and collaborators 4 carried out secondary analyses of data from the SPRINT and ACCORD trials, focusing on participants who did not have evidence of CKD at baseline. In the ACCORD trial, after 3 years the cumulative incidence of CKD was 10% in the intensive treatment group versus 4.1% in the standard treatment group, whereas in SPRINT, the incidence of CKD in the intensive treatment group was 3.5% versus 1.0% in the standard treatment group. The researchers rightly conclude that intensive BP lowering increases the risk of renal disease in individuals with Furthermore, it seems that appropriate BP values might need to be related to (and in the case of patient management, personalized to) the structural and functional status of the kidneys before and during treatment.
Whether the kidneys are adversely affected by the intensity of BP-lowering treatment will depend, at a minimum, on the general health of the individual, the medication that is being used to control BP, how quickly BP is brought under control, the total nephron count (which ranges from 400,000 to 2.4 million) and the presence of structural damage to the kidneys. However, aside from an assessment of an individual's general health and their cardiovascular haemodynamic status, most clinicians do not have this crucial information about the kidneys when treating hypertension. Thus, BP intervention trials should perhaps incorporate an assessment of these parameters or meaningful surrogates.
For years, the conventional wisdom was that healthy kidneys could regulate blood flow over a wide range of BPs that is usually compatible with the BP targets mentioned above. However, some medications used to treat hypertension, although extremely effective in controlling BP, might impair renal regulation of blood flow.
Results from animal studies might be illuminating in this regard. For example, we examined the haemodynamic and renal consequences of inhibiting the renin-angiotensin system (RAS) in rats with severe hypertension that were treated for 14 days with the angiotensin II receptor antagonist valsartan, the direct renin or without diabetes and caution that close monitoring of renal function in these patients is needed 4 . These findings elicit some considerations. Attempting to identify an 'optimal' systolic BP level (perhaps somewhere between 120-130 mmHg) that provides cardiovascular protection while preserving kidney function might be an understandable initial reaction. Although additional studies to identify this optimum BP seem warranted, the presence of many different variables in each individual will make it somewhat challenging to arrive at definitive conclusions. 
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NaTuRe ReviewS | NePhrology inhibitor aliskiren or both inhibitors 5 . Although all treatments markedly improved BP, cardiac hypertrophy and proteinuria, blind histological examination of the kidneys at 14 days unexpectedly detected tubular dilatation and tubular cell proliferation, interstitial and periglomerular fibrosis and focal vascular thickening of arterioles for all treatments compared with vehicle-treated rats. Remarkably, these alterations were most pronounced in rats that received dual treatment. Importantly, we found that proteinuria, which is commonly used as a marker of renal injury, improved in the treated rats, giving the false initial impression that no renal damage existed. In light of these results, a clear need exists to identify markers that accurately reflect the structural integrity of the kidneys.
Several factors might account for kidney damage resulting from intensive BP control (Fig. 1) . Although not formally investigated in our study, we postulated that the ability of the kidneys to regulate blood flow was impaired in rats treated with RAS inhibitors 5 . Interestingly, dual blockade of the RAS resulted in a marked increase in the number of renin-producing cells along the renal arterioles. In response to RAS inhibition, smooth muscle cells of the renal arterioles are known to adopt an endocrine phenotype that diminishes their contractility 6 and might explain the failure of these arterioles to regulate blood flow. Under these conditions, a substantial drop in BP could lead to renal ischaemia and subsequent structural damage. Furthermore, experimental or spontaneous mutations in RAS genes (in rodents and humans) or prolonged pharmacological inhibition of the RAS in early life results in concentric vascular hypertrophy of the renal arterioles 7 . Studies in renin-null mice showed that this vascular hypertrophy was due to the presence of concentric, disorganized layers of renin-lineage cells and smooth muscle cells, which thickened the vessel walls and narrowed their lumens 8 . The researchers suggested that renin-null cells might also secrete factors that stimulate the growth of adjacent smooth muscle cells; these factors might be useful biomarkers of early renal damage that precedes the development of functional deterioration.
Of note, permanent loss of kidney function is usually preceded by a substantial dropout of structurally damaged nephrons. As histological assessment during the evaluation of patients with hypertension or in the design of clinical trials is usually not indicated, developing biochemical markers and improved imaging technologies that better reflect renal structural integrity before and during treatment is imperative. These tools are necessary not only to assess the safety N e w s & V i e w s Renal cell carcinoma (RCC) is a common, deadly cancer that affects nearly 300,000 individuals and causes nearly 100,000 deaths worldwide each year. Clear cell RCC (ccRCC) is the most common of the three major histological subtypes of sporadic RCC, accounting for 75% of cases. An understanding of the genetic basis of ccRCC has provided a foundation for the development of targeted therapies for patients with advanced ccRCC. Three companion reports in Cell from a remarkable multicentre, prospective longitudinal cohort study of patients with ccRCC, referred to as TRACERx Renal (tracking renal cell cancer evolution through therapy), provide unique, exhaustively detailed insights into the complex genetic alterations that occur in the origin, evolution and progression to metastasis of ccRCC [1] [2] [3] .
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Three reports from the TRACERx Renal study delineate the precise origin and evolution of clear cell renal cell carcinoma in minute detail. The insights gained from these studies might provide improved disease prognostics and identify novel therapeutic targets.
